ZENITH20-2 is a multicentre, multicohort, open-label phase 2 trial that investigated poziotinib for previously treated advanced NSCLC patients with EGFR exon 20 insertions that demonstrated resistance to approved TKIs. Here, EGFR is linked to non-small cell lung carcinoma.